SCHEMBL9965985

SCHEMBL9965985

CN1C[C@@H]2[C@H](C1)[C@@H]2C(=O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPP5C P53041 2/20 0.36
TFPI2 P48307 2/20 0.36
PPP2CA P67775 1/20 0.36
NPY4R P50391 1/20 0.36
TDP1 Q9NUW8 4/20 0.36
POLB P06746 3/20 0.36
CTDSP1 Q9GZU7 1/20 0.35
ALDH1A1 P00352 2/20 0.33
APEX1 P27695 1/20 0.33
KDM4E B2RXH2 1/20 0.33
GMNN O75496 1/20 0.33
LMNA P02545 1/20 0.33
PMP22 Q01453 1/20 0.33
TP53 P04637 1/20 0.33
TSHR P16473 1/20 0.33
NFKB1 P19838 1/20 0.33
THPO P40225 1/20 0.33
CHRM4 P08173 1/20 0.32
CHRM3 P20309 1/20 0.32
CYP1A2 P05177 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18418128 1.00 PPP5C (0.36) PPP5CTFPI2PPP2CANPY4RTDP1
SCHEMBL16252754 1.00 PPP5C (0.36) PPP5CTFPI2PPP2CANPY4RTDP1
SCHEMBL13735630 1.00 PPP5C (0.36) PPP5CTFPI2PPP2CANPY4RTDP1
Hydrochloric Acid SCHEMBL20943288 0.97 TDP1 (0.37) PPP5CTFPI2PPP2CANPY4RTDP1
Hydrochloric Acid SCHEMBL20943293 0.97 TDP1 (0.37) PPP5CTFPI2PPP2CANPY4RTDP1
Hydrochloric Acid SCHEMBL20943290 0.97 TDP1 (0.37) PPP5CTFPI2PPP2CANPY4RTDP1
SCHEMBL23513695 0.84 ALDH1A1 (0.40) PPP5CTFPI2PPP2CANPY4RTDP1
SCHEMBL18418153 0.79 CYP1A2 (0.33) TDP1CYP1A2
SCHEMBL22249369 0.77 HDAC3 (0.32) SMN1; SMN2
SCHEMBL19051286 0.77 SSTR4 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240043420-A1 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ENLIVEN INC. 2024-02-08 US disclosed
EP-4225741-A1 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES Enliven Therapeutics, Inc. (US) 2023-08-16 EP disclosed
US-20190218180-A1 Cationic Lipid EISAI R&D MANAGEMENT CO., LTD. (JP) 2019-07-18 US disclosed
US-20180092880-A1 SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT 2018-04-05 US disclosed
US-9789082-B2 Somatostatin receptor subtype 4 (SSTR4) agonists CENTREXION THERAPEUTICS CORPORATION (US) 2017-10-17 US disclosed
US-20170014381-A1 NEW SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT 2017-01-19 US disclosed
US-9371282-B2 Somatostatin receptor subtype 4 (SSTR4) agonists CENTREXION THERAPEUTICS CORPORATION (US) 2016-06-21 US disclosed
US-20140343065-A1 New Somatostatin receptor subtype 4 (SSTR4) agonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-20 US disclosed
EP-2470021-B1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME (US) 2014-10-22 EP disclosed
US-8354403-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-01-15 US disclosed
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 US disclosed
WO-2011025690-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2011-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180092880-A1 SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS SSTR4, SSTR3, SSTR1 PPP5C 1273/4885TFPI2 3054/4885PPP2CA 1474/4885
US-20190218180-A1 Cationic Lipid NPC1L1, NPC1, LPCAT1 PPP5C 4701/4885TFPI2 4075/4885PPP2CA 4814/4885
US-20240043420-A1 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES ABL1, ABL2, BCR PPP5C 135/4885TFPI2 1608/4885PPP2CA 50/4885
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 PPP5C 2641/4885TFPI2 4143/4885PPP2CA 2534/4885
US-20170014381-A1 NEW SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS SSTR4, SSTR3, SSTR1 PPP5C 1127/4885TFPI2 3196/4885PPP2CA 1418/4885
US-20140343065-A1 New Somatostatin receptor subtype 4 (SSTR4) agonists SSTR4, SSTR3, SSTR1 PPP5C 1127/4885TFPI2 3196/4885PPP2CA 1418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.